Ardelyx
↗Waltham, Massachusetts, USA
Ardelyx is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing first-in-class medicines that meet significant unmet medical needs. The company focuses on gastrointestinal (GI) and cardiorenal diseases, leveraging its proprietary drug discovery platform to create minimally-systemic small molecules that act locally in the GI tract.
Ardelyx's primary commercial products are based on tenapanor, a first-in-class NHE3 inhibitor. These include IBSRELA, approved for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C), and XPHOZAH, approved to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis. The company is actively expanding its pipeline with new indications for tenapanor and next-generation inhibitors.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Cardiorenal and GI Therapeutics
SIZE & FINANCIALS
Employees:201-500
Revenue:$378M (2025)
Founded:2007
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$61.1M
Investors:New Enterprise Associates, CMEA Capital, Amgen Business Development, Two Seas Capital LP, Stonepine Capital Management
STOCK
Exchange:NASDAQ
Ticker:ARDX
Market Cap:$1.7B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:5
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 2 | Phase 4: 1
FDA Approvals:2
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Kyowa Kirin (Japan commercialization), Fosun Pharma (China development/commercialization), Knight Therapeutics (Canada commercialization)
COMPETITION
Position:Leader
Competitors:Ironwood Pharmaceuticals (Linzess), Bausch Health (Trulance), Sanofi (Renvela), Takeda (Amitiza), Akebia Therapeutics
LEADERSHIP
Key Executives:
Mike Raab - President & CEO
Sue Hohenleitner - CFO
Eric Foster - Chief Commercial Officer
Scientific Founders:Peter G. Schultz, Dominique Charmot
Board Members:David Mott (Chairman), Robert Bazemore, Muna Bhanji, Merdad Parsey
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ardelyx. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.